ArticleJAMA health forum2021
Measuring the Scope of Prior Authorization Policies: Applying Private Insurer Rules to Medicare Part B.
Article in JAMA health forum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Transcatheter Aortic Valve Replacement (TAVR) in Medicare Advantage and Medicare Fee-for-Service: Differences in Patient Characteristics, Utilization, and Outcomes.Circulation. Population health and outcomes · 2026Article
- Examination of insurance type and cancer treatments with administrative burdens and financial toxicity in a sample of cancer survivors.Journal of cancer survivorship : research and practice · 2026Article
- Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage and Traditional Medicare.JAMA internal medicine · 2026Article
- Prior Authorization Requirements in Medicare Advantage and County Social Vulnerability.The American journal of managed care · 2026Article
- Shifting barriers to health care access: from affordability to coverage issues.BMC health services research · 2026Article
- Quality assessment of large language model-generated prior authorization letters in nephrology.Frontiers in digital health · 2026Article
- Integrating Prior Authorization Into Clinical Workflows for Care Access and Practitioner Experience.JAMA network open · 2025Article
- Prior Authorization, Quantity Limits, and Step Therapy for Patient-Administered Antiemetics.JAMA network open · 2025Article
- Medigap Regulations Provide Protections For Beneficiaries, Especially After Health Shocks, But May Raise Premiums.Health affairs (Project Hope) · 2025Article
- Payment Source Shift for Surgical Care Among Veterans Enrolled in Medicare Advantage Plans.JAMA health forum · 2025Article
- Trends in Plan Offerings, Enrollment, and Premiums in Medicare Advantage and Medigap.Health services research · 2025Article
- Disparities in treatment delays among metastatic breast cancer patients: insights from nationwide electronic health records, 2011-2022.Breast cancer research and treatment · 2025Article
- Impact of payer rejections and out-of-pocket costs on patient access to bempedoic acid therapy.American journal of preventive cardiology · 2025Article
- The Burden of Insurance Prior Authorization on Cancer Care: A Review of Evidence From Radiation Oncology.Advances in radiation oncology · 2025Review
- Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.JAMA network open · 2024Article
- Resource Use and Care Quality Differences Among Medicare Beneficiaries Undergoing Chemotherapy.JAMA network open · 2024Article
- Perceptions of prior authorization burden and solutions.Health affairs scholar · 2024Article
- Trends in low-value cancer care during the COVID-19 pandemic.The American journal of managed care · 2024Article
- Prior authorization for FDA-approved PARP inhibitors in ovarian cancer.Gynecologic oncology reports · 2024Article
- Prior Authorization and Association With Delayed or Discontinued Prescription Fills.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Importance: Health insurers use prior authorization to evaluate the medical necessity of planned medical services. Data challenges have precluded measuring the frequency with which medical services can require prior authorization, the spending on these services, the types of services and clinician specialties affected, and differences in the scope of prior authorization policies between government-administered and privately administered insurance. Objectives: To measure the extent of prior authorization requirements for medical services and to describe the services and clinician specialties affected by them using novel data on private insurer coverage policies. Design Setting and Participants: Fee-for-service Medicare claims from 2017 were analyzed for beneficiaries in Medicare Part B, which lacks prior authorization. We measured the use of services that would have been subject to prior authorization according to the coverage rules of a large Medicare Advantage insurer and calculated the associated spending. We report the rates of these services for 14 clinical categories and 27 clinician specialties. Main Outcomes and Measures: Annual count per beneficiary and associated spending for 1151 services requiring prior authorization by the Medicare Advantage insurer; likelihood of providing 1 or more such service per year, by clinician specialty. Results: Of 6 497 534 beneficiaries (mean [SD] age, 72.1 [12.1] years), 41% received at least 1 service per year that would have been subject to prior authorization under Medicare Advantage prior authorization requirements. The mean (SD) number of services per beneficiary per year was 2.2 (8.9) (95% CI, 2.17-2.18), corresponding to a mean (SD) of $1661 ($8900) in spending per beneficiary per year (95% CI, $1654-$1668), or 25% of total annual Part B spending. Part B drugs constituted 58% of the associated spending, mostly accounted for by hematology or oncology drugs. Radiology was the largest source of nondrug spending (16%), followed by musculoskeletal services (9%). Physician specialties varied widely in rates of services that required prior authorization, with highest rates among radiation oncologists (97%), cardiologists (93%), and radiologists (91%) and lowest rates among pathologists (2%) and psychiatrists (4%). Conclusions and Relevance: In this cross-sectional study, a large portion of fee-for-service Medicare Part B spending would have been subject to prior authorization under private insurance coverage policies. Prior authorization requirements for Part B drugs have been an important source of difference in coverage policy between government-administered and privately administered Medicare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.